Tianjin Chase Sun Pharmaceutical Co Ltd (300026) fair value: what the stock is really worth
As of Oct 29, 2026: fair value (intrinsic value) of Tianjin Chase Sun Pharmaceutical Co Ltd stock ¥2.87, price ¥3.08, upside -6.7%, quality 51 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 28, 2026.
How to read this chart
60‑month range ¥2.89 – ¥9.01 · the ¥3.08 price screens above the ¥2.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 28, 2026.
Follow Tianjin Chase Sun Pharmaceutical Co in your weekly email
Every Wednesday you see whether Tianjin Chase Sun Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally.
Show moreShow less
The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices.
It serves the fields of immunity, cardiovascular and cerebrovascular diseases, respiratory system, and neurodegenerative diseases. The company was founded in 1996 and is headquartered in Tianjin, China.
Stock analysis
Tianjin Chase Sun Pharmaceutical Co Ltd (300026) currently trades at ¥3.08, while our model-based Fair Value estimate is ¥2.87, so the stock looks roughly fairly valued today (gap 7.2%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥2.52 per share, and 6 of the 26 models we run sit above the ¥3.08 price.
Bear case: the Economic Profit group reads lowest at ¥0.3200, and 20 of the 26 models stay below the price. Data coverage for this calculation is low.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Tianjin Chase Sun Pharmaceutical Co Ltd reported revenue of 5.8B CNY in FY2024 versus 6.5B CNY in FY2020, a compound −2.8%/yr. Reported net income was 21.5M CNY in FY2024, compounding −56.0%/yr from FY2020.
Key figures
Market cap 8.7B CNY (≈ $1.3B) Small · P/E ratio 308.0 · P/S ratio 1.31 · EPS (TTM) ¥0.0100 · Dividend yield 0.3% · Net margin 0.4% · Return on equity 0.2% · Return on assets (EBIT) 4.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (medium confidence).
What moves the price
The share trades about 22% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −24% fair-value upside, at −7%, 300026 screens cheaper than that median.
Fair Value models
Bear¥2.87Fair Value ¥2.87Bull¥2.87
Price ¥3.08 · Upside -6.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF¥3.16¥5.14¥9.9874
EPV¥0.3100¥0.3200¥0.320074
Residual Income¥1.85¥1.69¥1.5874
All 26 models by family
DCF Models
FCF DCF¥3.16¥5.14¥9.9874
Owner Earnings¥1.89¥3.50¥6.4271
5Y Revenue Exit¥1.28¥1.61¥1.9972
5Y EBITDA Exit¥2.06¥3.36¥5.1372
5Y P/E Exit¥1.28¥1.63¥1.9770
10Y Revenue Exit¥1.90¥2.52¥3.2266
10Y EBITDA Exit¥2.41¥3.81¥6.0665
10Y P/E Exit¥1.91¥2.52¥3.3263
Earnings-Based
Graham-Dodd¥0.0500¥0.3100¥0.430061
Lynch FV¥0.0900¥0.1300¥0.160059
PEG = 1.0¥0.0900¥0.1300¥0.160055
EPV¥0.3100¥0.3200¥0.320074
Dividend Discount
Gordon GGM¥0.3700¥0.6900¥0.980065
DDM Multi-Stage¥0.3700¥0.6200¥0.740065
Multiples
P/E Multiple¥0.1200¥0.1600¥0.200063
P/S Multiple¥0.0900¥0.1200¥0.150058
P/B Multiple¥8.24¥10.99¥13.7355
EV/EBIT¥0.3700¥0.4200¥0.470066
EV/EBITDA¥1.55¥2.00¥2.4467
EV/Revenue¥0.3200¥0.3700¥0.420054
Asset-Based
NCAV (Graham)¥0.8000¥1.21¥1.5155
Growth DCF
Growth DCF¥3.05¥5.51¥9.3873
Rev-Margin DCF¥1.28¥1.66¥2.1971
Economic Profit
Residual Income¥1.85¥1.69¥1.5874
ROIC Compounder¥0.3100¥0.3200¥0.320070
Growth Earnings
Growth-Adj P/E¥0.1300¥0.1800¥0.240065
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−5.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.9%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.4%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−40.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−41.0%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−41.0% vs −24.8%, slowing
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 1%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +0.3% a year for the price.
Compare Tianjin Chase Sun Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 576 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−7.3% · Above median
Profitability
Return on equity (12 months)0.2% · Below median
Return on assets0.2% · Below median
Net margin (12 months)0.4% · Below median
Operating margin (12 months)3.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)−24.6% · Bottom 25%
Dividend yield (12 months)0.3% · Bottom 25%
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Tianjin Chase Sun Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300026
Frequently asked questions
Is Tianjin Chase Sun Pharmaceutical Co Ltd (300026) overvalued or undervalued?
As of Oct 28, 2026, our model estimates a fair value of ¥2.87 versus a price of ¥3.08, about −7% upside (fairly valued).
What is the fair value of 300026?
Our model-based fair value for Tianjin Chase Sun Pharmaceutical Co Ltd is ¥2.87 (as of Oct 28, 2026), built from audited fundamentals. The current price: ¥3.08.
What is the quality score of 300026?
Tianjin Chase Sun Pharmaceutical Co Ltd has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
Our model-based price target is the fair value of ¥2.87 (as of Oct 28, 2026) from 26 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Tianjin Chase Sun Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at ¥2.87, about −7% upside versus a price of ¥3.08 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
Tianjin Chase Sun Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 4.3B CNY (latest available figure, as of Oct 28, 2026).
Does Tianjin Chase Sun Pharmaceutical Co Ltd pay a dividend?
Tianjin Chase Sun Pharmaceutical Co Ltd currently shows a dividend yield of 0.32% relative to its recent price (as of Oct 28, 2026).
What growth is priced into Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
For today's price to be fair in a discounted-cash-flow model, Tianjin Chase Sun Pharmaceutical Co Ltd would have to grow free cash flow by +2.0 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.9 % per year. As of Oct 28, 2026.
What discount rate (WACC) does the fair value of 300026 use?
Our models discount Tianjin Chase Sun Pharmaceutical Co Ltd at 10.4 %: a base by market capitalisation (small), damped by beta 0.02, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tianjin Chase Sun Pharmaceutical Co Ltd that is +2.0 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Tianjin Chase Sun Pharmaceutical Co Ltd (300026) delivered so far?
Over the past 5 years revenue at Tianjin Chase Sun Pharmaceutical Co Ltd grew +2.9 % a year. The price currently implies +2.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Tianjin Chase Sun Pharmaceutical Co Ltd (300026) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Tianjin Chase Sun Pharmaceutical Co Ltd (+2.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
The free-cash-flow yield on the price is 7.55 %: that much free cash flow Tianjin Chase Sun Pharmaceutical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tianjin Chase Sun Pharmaceutical Co Ltd it is ¥2.87 per share (as of Oct 28, 2026), against a price of ¥3.08. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Tianjin Chase Sun Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Oct 28, 2026, 300026 trades above its calculated fair value: price ¥3.08, fair value ¥2.87, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300026?
No. The price is what the market pays today (¥3.08); the fair value is what the company's own numbers justify (¥2.87). For Tianjin Chase Sun Pharmaceutical Co Ltd the two are ¥0.2070 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tianjin Chase Sun Pharmaceutical Co Ltd worth?
The market values Tianjin Chase Sun Pharmaceutical Co Ltd at about 8.7B CNY (market capitalisation, as of Oct 28, 2026). Per share that is ¥3.08; our models calculate a fair value of ¥2.87 per share.
What is the P/E ratio of 300026?
Tianjin Chase Sun Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 308.0 (as of Oct 28, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥2.87 is built from several models across several years. Other multiples: P/B 1.0, P/S 2.0, EV/EBITDA 18.0.
How solid is the balance sheet of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
Balance-sheet figures for Tianjin Chase Sun Pharmaceutical Co Ltd (as of Oct 28, 2026): return on equity 0.2%, debt of 0.06 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 300026 from its 52-week high?
Tianjin Chase Sun Pharmaceutical Co Ltd trades at ¥3.08, about 22% below its 52-week high of ¥3.94 and 7% above the low of ¥2.89 (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of ¥2.87 is for.
Which stocks are comparable to Tianjin Chase Sun Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tianjin Chase Sun Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Oct 28, 2026: price ¥3.08, calculated fair value ¥2.87 (−7%), Quality Score 51/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300026 calculated?
We run Tianjin Chase Sun Pharmaceutical Co Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥2.87, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Tianjin Chase Sun Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
The closing price on Oct 29, 2026 was ¥3.08. Our model-based fair value is ¥2.87, about −7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tianjin Chase Sun Pharmaceutical Co Ltd right now?
The price sits above even our optimistic bull case (¥2.87). The favourable scenario is already priced in. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Tianjin Chase Sun Pharmaceutical Co Ltd (300026) come from?
Earnings per share at Tianjin Chase Sun Pharmaceutical Co Ltd grew −2.0 % a year from 2013 to 2024. Broken into its drivers: revenue per share +8.8 %, EBIT margin −10.2 %, tax rate −0.4 %, residual (interest, one-offs) +0.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Tianjin Chase Sun Pharmaceutical Co Ltd
How large is the market capitalisation of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
The market capitalisation of Tianjin Chase Sun Pharmaceutical Co Ltd is 8.7B CNY (≈ $1.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
The price-to-sales ratio of Tianjin Chase Sun Pharmaceutical Co Ltd is 1.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
Earnings per share at Tianjin Chase Sun Pharmaceutical Co Ltd are ¥0.0100 (price ÷ EPS = P/E 308.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
The dividend yield of Tianjin Chase Sun Pharmaceutical Co Ltd is 0.3% (payout 100%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
The net margin of Tianjin Chase Sun Pharmaceutical Co Ltd is 0.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
The return on equity (ROE) of Tianjin Chase Sun Pharmaceutical Co Ltd is 0.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
On an EBIT basis the return on assets of Tianjin Chase Sun Pharmaceutical Co Ltd is 4.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
The operating margin of Tianjin Chase Sun Pharmaceutical Co Ltd is 3.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
Revenue at Tianjin Chase Sun Pharmaceutical Co Ltd is growing −24.6% versus a year earlier (3y avg −9.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tianjin Chase Sun Pharmaceutical Co Ltd (300026)?
Earnings per share at Tianjin Chase Sun Pharmaceutical Co Ltd are growing −21.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Tianjin Chase Sun Pharmaceutical Co Ltd (300026) hold?
Tianjin Chase Sun Pharmaceutical Co Ltd holds more cash than debt, 650M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Tianjin Chase Sun Pharmaceutical Co Ltd in the live analysis
One click puts Tianjin Chase Sun Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 28, 2026